FDA clears Apple’s sleep apnea detection feature for use. Here’s how it works

FDA clears Apple’s sleep apnea detection feature for use. Here’s how it works


Tim Cook, chief executive officer of Apple Inc., during an event at Apple Park campus in Cupertino, California, US, on Monday, Sept. 9, 2024. Apple Inc. unveiled a new version of its smartwatch with a bigger screen and the ability to detect sleep apnea, part of an event Monday that will also include the iPhone 16 smartphone. Photographer: David Paul Morris/Bloomberg via Getty Images

Bloomberg | Bloomberg | Getty Images

The U.S. Food and Drug Administration on Monday cleared Apple‘s new sleep apnea detection feature for use, which means it will come to the Apple Watch Series 9, Series 10, and Ultra 2 later this month. 

Sleep apnea is a sleep disorder that causes a person’s breathing to repeatedly stop and start throughout the night. The condition affects more than 30 million people in the U.S., but only around 6 million are diagnosed, according to the American Medical Association. If it goes untreated, sleep apnea can cause fatigue and lead to more serious health issues like heart problems, hypertension and Type 2 diabetes. 

“We are so excited about the incredible impact this feature can make for the millions of people living with undiagnosed sleep apnea,” Dr. Sumbul Desai, vice president of health at Apple, said in the feature’s launch video.

Apple’s sleep apnea detection feature marks the company’s latest attempt to position its wearables as a cheaper, simpler alternative to many existing health-care tests and devices. And the sleep disorder market could prove to be lucrative. 

To get evaluated for sleep apnea, for instance, patients typically participate in an at-home test or an in-lab test where they’re monitored overnight. Prices vary depending on insurance coverage, but the average in-lab test costs $3,000, according to a 2022 study in the Journal of Primary Care & Community Health. 

At-home tests are often less expensive, but they can still cost hundreds of dollars. The at-home sleep apnea test from Sleep Doctor costs $189, for example. Apple’s newest watch, the Series 10, starts at $399. 

Apple announces Apple Watch Series 10 with thinnest design ever, biggest display yet

Apple’s sleep apnea detection feature is “potentially a game changer” for patients who have been reluctant to seek out testing, said Dr. David Kuhlmann, a physician who has treated sleep disorders for nearly two decades in Missouri. Kuhlmann also serves on the board of the American Academy of Sleep Medicine, which is a professional society for sleep medicine clinicians.  

Kuhlmann said the feature could be especially helpful for patients who sleep alone, and he thinks a lot of people will be surprised to find out they’re showing signs of sleep apnea.  

Even so, Kuhlmann said users should approach Apple’s sleep apnea data with some caution, as readings could be erroneous. He said it is unlikely that insurance companies will begin paying for sleep apnea therapies like CPAP machines based on Apple Watch data alone, which is why it is important for patients to follow up with their healthcare providers to get an official diagnosis. 

“People do need to be diagnosed in order to be treated,” Kuhlmann told CNBC in an interview. 

Kuhlmann said the feature will likely cause an increase in visits to health care providers, which could ultimately reduce costs for U.S. the health-care system overall. Ideally, if patients catch sleep apnea earlier, they can avoid paying for treatments for more serious conditions down the line.

“By finding out that they have these underlying sleep disorders and getting them treated, it could potentially actually help save expenses and help improve quality of life.”

How it works 

Apple Watch Series 10 sleep apnea alert.

Apple Inc.

Apple’s sleep apnea detection feature works by analyzing a new metric that the company calls “breathing disturbances.” The Apple Watch identifies breathing disturbances by using an accelerometer to measure movements at the wrist that indicate disruptions to normal breathing patterns. 

Users can view their nightly metrics in the Health app, where they’ll be classified as either “elevated” or “not elevated,” i.e., normal. Apple will analyze this breathing disturbance data once a month and notify people if they show “consistent signs” of severe or moderate sleep apnea. Users can view their data over a one-month, six-month or one-year period. 

The Apple Watch Series 10 supports an 18-hour battery life, so people who are interested in using this feature will likely need to charge their device during the day.

Apple can also generate a report that users can bring to their doctors to discuss next steps. The report includes three months’ worth of breathing disturbance data as well as some additional information, the company said. Users can access educational materials within the Health app as well. 

Apple said the notification algorithm was developed with “an extensive data set of clinical-grade sleep apnea tests,” and that the feature was validated in a clinical study.

“Now I’m jonesing to get an Apple [Watch] so I can try it out on myself,” Kuhlmann said.



Source

Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly
Health

Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly

Celsopupo | Istock | Getty Images Zealand Pharma on Thursday outlined an ambitious five-year strategy for its anti-obesity portfolio Thursday, spotlighting how growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more of these medicines near market entry. The new strategy, “Metabolic Frontier 2030,” comes as Zealand […]

Read More
Eli Lilly to build  billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs
Health

Eli Lilly to build $6 billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs

Eli Lilly CEO David A. Ricks speaks at a press conference at Generation Park in Houston, Monday, Sept. 23, 2025. The company announced plans for a $6.5 billion biomanufacturing plant in north Houston. (Raquel Natalicchio/Houston Chronicle via Getty Images) Raquel Natalicchio | Houston Chronicle | Getty Images Eli Lilly on Tuesday said it will spend […]

Read More
A biotech stock for investors scared to invest in the risky industry
Health

A biotech stock for investors scared to invest in the risky industry

Citigroup thinks investors should consider Ligand Pharmaceuticals for a more conservative bet on the biotech industry. The bank initiated the biotech stock at a buy rating and price target of $270, implying upside of 46% from Ligand’s Monday closing price of $184.67. Shares have soared nearly 79% this year. LGND YTD mountain LGND YTD chart […]

Read More